Introduction
Biofourmis is a Boston-based global technology company founded in 2015 that delivers AI-driven remote patient monitoring and virtual care-at-home programs. Maulik Majmudar, MD, co-founded Biofourmis and serves as chief medical officer per the company’s about page reviewed in July 2026 — a clinical leadership role reflecting Biofourmis’s positioning as a care delivery platform, not merely a device analytics vendor. David Koretz serves as chief executive officer.
Biofourmis combines wearable biosensors, FDA-cleared predictive algorithms, virtual clinical teams, and EHR integration to support hospital-level acute care, post-discharge monitoring, and chronic disease management in patients’ homes. Majmudar’s clinical voice in partnership releases emphasizes configurable programs for health systems at different maturity stages — a message tailored to buyers burned by RPM pilots that lacked escalation pathways.
What the company does
Biofourmis collects continuous and episodic physiological data from medical-grade wearables and patient-reported outcomes, analyzing signals through its Biovitals AI engine to detect deterioration early and trigger proactive interventions. The platform supports hospital-at-home admissions, post-acute RPM, virtual specialty care through Biofourmis Care, and digital clinical trial acceleration via Biofourmis Connect — the life-sciences division ActiGraph acquired in January 2025 per Biofourmis newsroom announcements.
Virtual clinical teams staffed by Biofourmis or partner health systems respond to algorithm-triggered alerts — the operational layer that distinguishes Biofourmis from wearable vendors selling hardware without escalation pathways. Majmudar’s clinical leadership role shapes protocol design for conditions such as heart failure, COPD, and post-surgical recovery where early deterioration signals justify home-based intervention.
Who it serves
Biofourmis sells to integrated delivery networks expanding care-at-home strategies — AdventHealth’s January 2025 collaboration in Central Florida deploys Biofourmis for hospital-at-home launch at AdventHealth Winter Park plus post-acute RPM for continuity after discharge. Payers and employers access virtual specialty and chronic care programs; biopharma customers previously used Biofourmis Connect for decentralized trial data before the ActiGraph transaction. Majmudar frequently represents clinical design in partnership releases, emphasizing configurable technology for health systems at different care-at-home maturity stages.
Post-acute care teams benefit when RPM continues seamlessly after hospital-at-home discharge — AdventHealth’s stated whole-person continuity model depends on one platform vendor spanning acute and post-acute phases rather than stitched point tools.
Company background
Majmudar co-founded Biofourmis in 2015 in Boston, drawing on cardiology and digital health experience to address access and affordability gaps through technology. The company expanded globally with offices in Singapore and India while signing large health-system contracts including WellSpan and Lee Health programs referenced in Biofourmis news materials. In October 2024 Biofourmis merged with CopilotIQ to broaden in-home chronic care capabilities, creating an end-to-end platform spanning pre-surgical through acute and chronic home care cited in AdventHealth release boilerplate.
David Koretz leads commercial and operational scaling as CEO while Majmudar remains the clinical voice in partnership announcements — a division of labor common among digital health companies bridging technology and care delivery.
Product and AI capabilities
Biovitals applies machine learning to multivariate time-series data from wearables — heart rate, respiration, activity, ECG contexts — generating clinical insights that support nurse triage and physician escalation. Biofourmis emphasizes FDA-cleared algorithms and arrhythmia or fall detection integrated with personal emergency response in hospital-at-home settings. Epic EHR interoperability featured in the AdventHealth program reduces duplicate documentation and supports clinician confidence that home monitoring meets inpatient safety expectations.
Configurable branching logic in Biofourmis workflows lets health systems tune escalation rules to local staffing — a practical requirement when nurse-to-patient ratios differ between community hospitals and academic centers.
Key developments
2015: Biofourmis founded in Boston; Maulik Majmudar, MD, co-founder and CMO. January 6, 2025: AdventHealth collaboration for hospital-at-home and RPM (official newsroom). January 7, 2025: ActiGraph acquired Biofourmis Connect life-sciences business (Biofourmis newsroom).
October 2024 CopilotIQ merger, referenced in Biofourmis AdventHealth release boilerplate, preceded 2025 health-system wins — consolidating chronic and acute home-care capabilities before large IDN contracts expanded.
Why it matters
Biofourmis matters because hospital-at-home programs require operational partners, not just RPM dashboards — predictive AI alone does not replace virtual nursing, device logistics, or EHR write-back. AdventHealth’s 2025 selection validates Biofourmis’s full-stack model at a major U.S. faith-based health system. Majmudar’s CMO role keeps clinical credibility central as AI RPM vendors compete with health-system-built programs and payer-owned virtual care lines.
Health systems scaling care-at-home should compare readmission and satisfaction metrics before and after platform switches — Biofourmis cites expected quality tracking at 30 and 90 days in large deployments such as WellSpan, a discipline smaller pilots often skip.
Sector context
Biofourmis belongs in Brel’s AI in healthcare coverage under digital health and remote monitoring, distinct from clinical documentation AI such as Corti or Suki AI. Readers comparing RPM vendors should evaluate FDA algorithm clearances, EHR integration depth, and in-house clinical staffing — not wearable hardware alone.
Hospital-at-home waivers and payer policy shifts materially affect addressable market for vendors like Biofourmis — technology capability is necessary but not sufficient without reimbursement alignment in each health system’s market.
Sources and references
Biofourmis AdventHealth news release (January 6, 2025) and About leadership page.
- Biofourmis — AdventHealth collaboration (biofourmis.com, January 6, 2025)
- Biofourmis — About / leadership (biofourmis.com)
Reviewed July 10, 2026. Maulik Majmudar, MD, is co-founder and CMO; David Koretz is CEO.